What was Bayer's adjusted Q2 EBITDA, and how did it compare to analyst expectations?

Bayer's second-quarter adjusted EBITDA was €2.14 billion ($2.46 billion), which exceeded the analyst consensus expectation of €1.94 billion posted on the company's website.

What recent legal development helped reduce Bayer's litigation risk related to Roundup, and what was its impact on the company?

In June, the U.S. Supreme Court reined in thousands of lawsuits claiming Bayer's Roundup weedkiller causes cancer, removing the threat of billions of dollars in additional damages and settlements — a development that provided a boost to CEO Bill Anderson and contributed to a subsequent ~19% gain in Bayer's share price.

Bayer posts unexpected 1.9% gain in Q2 adjusted profit

Aug 3, 2026

Bayer reported an unexpected 1.9% rise in Q2 adjusted profit driven by strong seed technology sales and reduced legal risks from Roundup rulings. The company also lowered its net debt forecast following a €3 billion sale of a contraceptive unit stake.

reuters

2026-05-12

Bayer maintains 2026 forecast; Q1 earnings beat estimates

2026-05-26

Bayer's India unit posts quarterly profit rise on crop protection boost

2026-08-03

Bayer posts unexpected 1.9% gain in Q2 adjusted profit

Bayer posts unexpected 1.9% gain in Q2 adjusted profit

FAQ